Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases

ConclusionDosimetric results show that the ADs for critical organs and total body are within the safety limit and with high bone retention. It is a promising radiopharmaceutical alternative for the targeted treatment of bone metastases, controlling its progression, and improving the survival and quality of life of patients with advanced bone metastasis.

http://link.springer.com/10.1186/s13550-024-01094-6

Source: EJNMMI Research - March 22, 2024 Category: Radiology Source Type: research